Ferrero Paolo, Iacovoni Attilio, D'Elia Emilia, Vaduganathan Muthiah, Gavazzi Antonello, Senni Michele
Dipartimento Cardiovascolare, Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy.
Dipartimento Cardiovascolare, Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy; Internal Medicine Department, Pavia University, Pavia.
Int J Cardiol. 2015 Jun 1;188:1-9. doi: 10.1016/j.ijcard.2015.03.154. Epub 2015 Mar 26.
Survival in patients with heart failure in the last two decades has significantly improved, owing to availability of new drugs, devices, and technologies. However, these new therapeutic tools are often costly and not without attendant risks. Thus, accurate and reproducible risk stratification is required to assess appropriateness of therapy. Although a growing body of evidence has characterized various predictors of poor outcomes, the application of comprehensive prognostic models in clinical practice remains limited. Herein, we critically evaluate the utility of prognostic scores in heart failure, discussing the strategies to select the most efficient and appropriate risk estimator in the individual patient.
在过去二十年中，由于新型药物、设备和技术的出现，心力衰竭患者的生存率有了显著提高。然而，这些新的治疗手段往往成本高昂且并非没有伴随风险。因此，需要准确且可重复的风险分层来评估治疗的适宜性。尽管越来越多的证据已明确了各种不良预后的预测因素，但综合预后模型在临床实践中的应用仍然有限。在此，我们批判性地评估心力衰竭预后评分的效用，讨论为个体患者选择最有效且合适的风险评估指标的策略。
